FDA product approval
approved product. Zepbound; Mounjaro is a separate labeled product.
GLP-1 and incretin · compound · checked 2026-10-09
Tirzepatide
Tirzepatide hits GIP and GLP-1 receptors. Zepbound and Mounjaro are separate FDA-approved products with their own labels. Compounded or research-market tirzepatide does not carry those approvals. This page keeps the label evidence and the research-market listings apart.
Last checked Oct 9, 2026 by PepBear. Not medical advice.
- FDA product
- approved product
- Compounding
- not established
- Research
- product specific
- Sport
- unknown
What is Tirzepatide?
Other names in the library include Zepbound, Mounjaro, T-10, and T-30. Approved-product evidence applies to the labeled pen in DailyMed. A 10 mg or 30 mg research vial is a seller listing. It is not a substitute pen. It does not let you copy the label schedule.
GIP and GLP-1 receptor agonist.
Regulatory status, dated 2026-10-09
Compounding
not established. Compounded products do not carry FDA product approval; legal eligibility is not established here.
Research
product specific. People meeting labeled weight-management or obstructive-sleep-apnea criteria; other approved products have different indications.
Sport
unknown. Not individually verified; consult your sport authority.
What the cited papers actually measured
SURMOUNT-1 (PMID 36356202) reported weight results for tirzepatide versus placebo in adults with obesity, first as a study drug and then as a labeled product. The current Zepbound label has boxed warnings, including thyroid C-cell tumor risk in rodents and do-not-use rules for MTC and MEN2. Stomach reactions, pancreatitis, and kidney injury after dehydration show up among label warnings. Food leaving the stomach more slowly can change how oral drugs absorb. Those are label facts. This website does not tell you to start therapy.
We mark the cited papers as A. That is our label for how strong those papers are. It does not say the compound works.
How long it lasts, how you store it, listed sizes
The catalog does not record a single hour value. The current Zepbound label reports approximately 5–6 days; no falsely precise single value is supplied.
The vendor file lists 10 mg and 30 mg research sizes. Approved pens have their own storage carton. Keep those instructions separate.
U-100 math for listed Tirzepatide sizes. Each cell is micrograms per syringe mark if you add that much liquid. The table does the same math as the calculator. It does not pick an amount for you.
| Listed vial | 1 mL liquid | 2 mL liquid | 3 mL liquid |
|---|---|---|---|
| 10 mg | 100 | 50 | 33.3 |
| 30 mg | 300 | 150 | 100 |
Risks and mix-ups already on the record
- Gastrointestinal reactions, pancreatitis and dehydration-related kidney injury are among label warnings.
- Personal or family medullary thyroid carcinoma, MEN2, or serious hypersensitivity: see the full product label.
- Insulin and sulfonylureas can increase hypoglycemia risk; delayed gastric emptying can affect oral medicines.
- The label warns of reduced oral hormonal contraceptive efficacy; discuss alternative or additional contraception with the prescribing clinician.
People using PepBear often log: Existing clinician-directed records, symptoms and dated health measurements. Record missing data; trends do not demonstrate causation.
Sources
- Approved product label · checked 2026-10-09
- Zepbound DailyMed label · checked 2026-10-09
- SURMOUNT-1 (PubMed 36356202) · checked 2026-10-09
- FDA concerns about unapproved GLP-1 drugs · checked 2026-10-09
Questions people ask
Is a research tirzepatide vial the same as Zepbound?
Zepbound is a specific approved product. Research-market vials are not that product. They do not inherit its approval or proven sameness.
Where do the unit numbers come from?
From the mass and liquid you type and a U-100 scale of 100 marks per mL. The page never fills a medical amount.
Related cards
A licensed clinician must interpret the evidence for your situation. This entry provides education, not treatment instructions. Not medical advice. PepBear does not pick a dose, a cycle, or a seller.